RemeGen Co Ltd
SSE:688331

Watchlist Manager
RemeGen Co Ltd Logo
RemeGen Co Ltd
SSE:688331
Watchlist
Price: 103.53 CNY -0.07% Market Closed
Market Cap: 58.4B CNY

Operating Margin

-38.2%
Current
Improving
by 68.1%
vs 3-y average of -106.3%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-38.2%
=
Operating Income
¥-850.8m
/
Revenue
¥2.2B

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-38.2%
=
Operating Income
¥-850.8m
/
Revenue
¥2.2B

Peer Comparison

Country Company Market Cap Operating
Margin
CN
RemeGen Co Ltd
SSE:688331
58.4B CNY
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
382B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.9B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
160.4B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
117.1B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.9B USD
Loading...
AU
CSL Ltd
ASX:CSL
86.3B AUD
Loading...
NL
argenx SE
XBRU:ARGX
42.6B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
48.2B USD
Loading...
No Stocks Found

Market Distribution

Lower than 90% of companies in China
Percentile
10th
Based on 8 544 companies
10th percentile
-38.2%
Low
-409 046.1% — -1.4%
Typical Range
-1.4% — 10.3%
High
10.3% — 876.4%
Distribution Statistics
China
Min -409 046.1%
30th Percentile -1.4%
Median 4.2%
70th Percentile 10.3%
Max 876.4%

RemeGen Co Ltd
Glance View

Market Cap
58.4B CNY
Industry
Biotechnology

In the bustling landscape of China's biopharmaceutical industry, RemeGen Co Ltd stands as a beacon of innovation and determination. Founded in 2008 and headquartered in Yantai, the company swiftly positioned itself as a frontrunner in the development of novel biologic therapies. With its operation straddling cutting-edge research and development facilities and state-of-the-art production capabilities, RemeGen focuses on addressing unmet medical needs in the realms of oncology and autoimmune diseases. Their work fundamentally consists of harnessing the power of human biology to create targeted therapies, a task which involves a rigorous process of discovery, clinical trials, and regulatory approvals before a drug can be brought to market. The company's business model relies significantly on its ability to advance promising candidates through the clinical pipeline and secure partnerships with international pharmaceutical giants. This not only helps in sharing the financial risks associated with drug development but also accelerates market access for its therapies. Revenue streams for RemeGen primarily come from sales of its proprietary drugs, licensing agreements, and milestone payments tied to research achievements or commercial successes. By aligning with global standards for drug development, RemeGen not only nurtures its own product portfolio but also attracts strategic collaborations, making it a formidable player in the global life sciences ecosystem.

Intrinsic Value
71.85 CNY
Overvaluation 31%
Intrinsic Value
Price
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-38.2%
=
Operating Income
¥-850.8m
/
Revenue
¥2.2B
What is RemeGen Co Ltd's current Operating Margin?

The current Operating Margin for RemeGen Co Ltd is -38.2%, which is above its 3-year median of -106.3%.

How has Operating Margin changed over time?

Over the last 3 years, RemeGen Co Ltd’s Operating Margin has decreased from 12.8% to -38.2%. During this period, it reached a low of -149.7% on Jun 30, 2023 and a high of 12.8% on Aug 30, 2022.

Back to Top